Limited Uptake of Core Outcome Set in Coronary Artery Disease Trials Despite 2015 Standardization Effort
核心洞察
Analysis of 433 coronary artery disease (搜索) trials reveals low adoption of standardized outcome measures, with only 11.5% of core outcomes reported before 2015 and minimal improvement afterward.
Procedural interventions (45.0%) and all-cause mortality (40.9%) were the most commonly reported outcomes, while patient-centered measures like dyspnea (搜索) (2.8%) remained severely underreported.
Study identifies key barriers to implementation including limited awareness among researchers, broad disease definitions, and preference for custom outcome measures in clinical trials.
A comprehensive analysis of clinical trials registered on ClinicalTrials.gov (搜索) has revealed disappointing uptake of standardized outcome measures for coronary artery disease (搜索) (CAD) research, despite efforts to improve consistency across studies.
The investigation examined 433 phase III/IV randomized controlled trials (RCTs) registered between May 2010 and June 2023, evaluating adherence to the Core Outcome Set (COS) established by McNamara et al. in 2015 through the International Consortium for Health Outcomes Measurement (搜索) (ICHOM (搜索)).
Current Implementation Status
The analysis showed that before the COS publication in 2015, trials reported an average of just 11.5% of the standardized outcomes. While there was a slight increase in reporting after 2015, the improvement was not statistically significant (p = 0.012). Among the 23 defined core outcomes, procedural interventions (45.0%) and all-cause mortality (40.9%) were most frequently reported, while critical measures such as acute renal failure (搜索) (2.1%) and patient-reported dyspnea (搜索) (2.8%) were rarely included.
Trial Characteristics and Outcome Reporting
The study encompassed a diverse range of trials, with a median enrollment of 243 participants and median duration of 32 months. Pharmacologic interventions dominated the landscape, representing 68.4% of trials, followed by percutaneous interventions at 13.2%.
A weak but statistically significant correlation was found between trial size and COS adherence (r = 0.27, p < 0.001). Recruitment status significantly influenced adherence (p < 0.001), though geographical location and sponsor type showed no meaningful impact on outcome reporting patterns.
Barriers to Implementation
Several factors appear to be hindering widespread adoption of the standardized outcomes:
- Limited awareness among trial designers and researchers
- Broad definition of CAD within the COS framework
- Complexity of implementing all 23 core outcomes
- Researcher preference for custom outcome measures
- Underemphasis on patient-reported outcomes
Impact on Research Quality
The continued lack of standardization poses significant challenges for evidence synthesis and meta-analyses in CAD research. None of the examined trials reported all applicable items from the COS, and the average percentage of reported outcomes remains below 25%, hampering efforts to compare results across studies effectively.
Future Directions
Experts suggest several approaches to improve COS adoption:
- Development of more specific outcome sets for CAD subgroups
- Enhanced educational initiatives for researchers
- Streamlining of core outcomes to focus on essential measures
- Greater emphasis on patient-centered outcomes
- Improved dissemination strategies for COS guidelines
The findings underscore the need for continued efforts to standardize outcome reporting in CAD clinical trials, with particular attention to balancing comprehensive assessment with practical implementation considerations.